{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219422","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2026-05-12T20:10:17+00:00","discovered_at":"2026-05-12T20:11:00.300712+00:00","generated_at":"2026-05-12T21:07:48.687593+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kura Oncology Q1 2026: $5.8M KOMZIFTI net revenue in first full commercial quarter; cash $580.8M","bullets":["Net product revenue $5.8M from KOMZIFTI in first full commercial quarter; 85 new patient starts, 157 total prescriptions.","Net loss $73.3M (Q1 2025: $57.4M); R&D expense $65.3M, SG&A $31.6M on commercialization investments.","Cash $580.8M plus $180M anticipated Kyowa Kirin payments expected to fund ziftomenib program through 2028.","Payer coverage >93% across >12M lives; early adoption includes repeat use, switching from other menin inhibitors.","Multiple 2026 catalysts: EHA updated KOMET-007 data, ASCO darlifarnib/adagrasib data, KOMET-008 preliminary data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219422","json":"https://secwatch.observer/filing/0001193125-26-219422.json","markdown":"https://secwatch.observer/filing/0001193125-26-219422.md","text":"https://secwatch.observer/filing/0001193125-26-219422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/0001193125-26-219422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/kura-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:07:48.687593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9be20403c61ac2be364eb7b08ad0f97af752f09a","claim":"Kura Oncology, Inc. reported first quarter ended March 31, 2026 results: revenue $5.8 million.","evidence_excerpt":"identified as being incorporated therein by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Kura Oncology Reports FIRST Quarter 2026 Financial Results – $5.8 million in KOMZIFTITM (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/0001193125-26-219422-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$5.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}